Caredx Stock Price, News & Analysis

CareDx has completed a $50 million share repurchase program, buying back approximately 5% of its outstanding shares. The company reported strong performance with seven consecutive quarters of testing services growth and Q1 revenue of $84.7 million, up 18% year-over-year. CareDx maintains a strong financial position with $231 million in cash and equivalents and no debt. The Board has authorized a new $50 million share repurchase program for the next 24 months. CEO John W. Hanna expressed confidence in the company's growth trajectory, targeting $500 million in revenue and 20% adjusted EBITA by 2027.

CareDx (NASDAQ: CDNA), a precision medicine company specializing in transplant healthcare solutions, has announced its participation in three major upcoming investor conferences in May and June 2025:

- Craig-Hallum 22nd Annual Institutional Investor Conference in Minneapolis on May 28
- Jefferies Global Healthcare Conference 2025 in New York with a presentation on June 5 at 10:30 a.m. ET
- Goldman Sachs 46th Annual Global Healthcare Conference in Miami featuring a fireside chat on June 9 at 3:20 p.m. ET

Webcasts for the June 5th and June 9th events will be available through CareDx's Investor Relations website.

CareDx reported strong Q1 2025 financial results with total revenue reaching $84.7 million, an 18% year-over-year increase. The company achieved its seventh consecutive quarter of growth in testing services, with volume rising to 47,100 tests.

Key highlights include:

• Testing services revenue: $61.9 million (+15% YoY)
• Patient and Digital Solutions revenue: $12.0 million (+24% YoY)
• Product revenue: $10.8 million (+26% YoY)

While reporting a GAAP net loss of $10.4 million, the company showed significant improvement with non-GAAP net income of $5.4 million and positive adjusted EBITDA of $4.6 million. CareDx maintains a strong financial position with $231 million in cash and no debt. The company reaffirmed its 2025 revenue guidance of $365-375 million and introduced expanded indications for AlloSure Testing Services.

CareDx presented new data on AlloSure Lung at the 2025 International Society for Heart and Lung Transplantation Meeting in Boston. The findings showcase significant advancements in transplant monitoring technology.

Key highlights from the research include:

• AlloSure Lung successfully detected acute cellular rejection onset and treatment response through surveillance monitoring
• The technology was used to monitor Tacrolimus inhalation powder safety in lung transplant patients with renal issues
• The ALAMO study revealed AlloSure Lung may predict Chronic Lung Allograft Dysfunction (CLAD)
• Higher AlloSure dd-cfDNA levels early post-transplant were linked to restrictive allograft syndrome (RAS)

The research, presented across 8 abstracts including 2 oral presentations, also demonstrated that the AlloHome remote monitoring system improved patient care efficiency and reduced staff workload. These findings suggest potential improvements in long-term outcomes for lung transplant patients.

CareDx (NASDAQ: CDNA) announced the presentation of 60 abstracts, including 19 oral presentations, at the 2025 International Society for Heart and Lung Transplantation Meeting. The presentations showcase data from 92 transplant centers demonstrating the clinical importance of CareDx's transplant testing solutions.

Key findings from the SHORE study revealed that HeartCare is prognostic of long-term graft outcomes independent of biopsy results. The study showed that dual-positive HeartCare results predict worse outcomes even with normal biopsy results, while early surveillance with HeartCare achieved similar 5-year survival rates with significantly fewer biopsies compared to traditional methods.

The company will host two sponsored symposia featuring experts from leading transplant centers discussing HeartCare and AlloSure Lung applications in clinical decision-making. Research demonstrated HeartCare's effectiveness in monitoring rejection across diverse patient populations, including women, Black Americans, and patients with chronic kidney disease.

CareDx (CDNA) has announced the granting of inducement stock awards to Jennifer Foley, their newly appointed Chief Product Officer, on April 7, 2025. The compensation package includes:

- 36,231 restricted stock units (RSUs) under the 2016 Inducement Equity Incentive Plan
- Performance-based stock units (PSUs) with 15,528 shares at target levels and up to 31,056 shares at maximum performance levels under the 2019 Inducement Equity Incentive Plan

The RSUs will vest over four years, with 25% vesting after the first year and 1/16th vesting quarterly thereafter. The PSUs have a two-year performance period plus one year of time-based vesting, with 50% eligible to vest on February 1, 2026, and the remaining 50% vesting in equal installments on February 1, 2027, and 2028, subject to performance goals and continued employment.

CareDx (Nasdaq: CDNA), a company specializing in transplant healthcare solutions, has announced it will release its first quarter 2025 financial results after market close on Wednesday, April 30, 2025. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results.

Interested participants can join the call by dialing 1-800-445-7795 (domestic) or 1-785-424-1699 (international) with Conference ID: CareDx. A webcast will be available in the Events & Presentations section of CareDx's Investor Relations website.

CareDx (CDNA) has announced two major expansions for its AlloSure® testing services. The first expansion extends AlloSure Heart testing to pediatric heart transplant patients under 15 years old, including infants. Studies show the test can detect rejection types ACR and AMR in pediatric patients, with one study demonstrating an 81% reduction in surveillance biopsies.

The second expansion validates AlloSure Kidney for simultaneous pancreas-kidney (SPK) transplant patients. Both expansions have received approval from the New York State Clinical Laboratory Evaluation Program. The kidney test helps differentiate patients at increased rejection risk from those with low rejection likelihood.

These expansions address significant market opportunities, considering that over 4,500 heart transplants were performed in the U.S. in 2024 (10% under age 18) and more than 700 patients received SPK transplants in the same year.

CareDx (CDNA) reported strong financial results for Q4 and full year 2024. The company achieved full-year revenue of $333.8 million, up 19% year-over-year, with testing services revenue growing 19% to $249.4 million.

Q4 2024 highlights include revenue of $86.6 million (+32% YoY), testing services revenue of $63.8 million (+37% YoY), and testing volume of 45,500 (+14% YoY). The company reported GAAP net income of $87.7 million for Q4 and $52.5 million for the full year.

CareDx ended 2024 with $261 million in cash and no debt. The Board authorized a $50 million share repurchase program. For 2025, the company projects revenue between $365-375 million and adjusted EBITDA of $29-33 million.